The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
The FDA has approved Breyanzi (lisocabtagene maraleucel) for the treatment of previously treated adults with relapsed or refractory mantle cell lymphoma.
Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi ® (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma .
The majority of patients that responded to obe-cel showed durable responses with the potential for a long-term plateau of survival outcomes40% patients are in ongoing remission without subsequent stem.